Cytek Biosciences, Inc. Financials
This page shows Cytek Biosciences, Inc. (CTKB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cytek’s sales plateau met deteriorating unit economics and heavier overhead, pushing the business from thin cash generation back into burn.
Between FY2024 and FY2025, revenue was almost unchanged near$200M , but gross margin fell from55.4% to51.8% while SG&A jumped from$43.1M to$58.9M ; that combination explains why the operating loss widened to-$40.4M without any real top-line decline. The much larger net loss of-$66.5M versus free cash outflow of only-$8.8M , alongside income tax expense of$36.7M , indicates FY2025 earnings were hurt more by below-operating and non-cash effects than by the year’s underlying cash drain.
Margin compression is not a one-year anomaly: gross margin has fallen from
Balance-sheet liquidity is still substantial, but the buffer is shrinking: cash declined from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cytek Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cytek Biosciences, Inc. has an operating margin of -20.0%, meaning the company retains $-20 of operating profit per $100 of revenue. This below-average margin results in a low score of 22/100, suggesting thin profitability after operating expenses. This is down from -10.2% the prior year.
Cytek Biosciences, Inc.'s revenue grew a modest 0.5% year-over-year to $201.5M. This slow but positive growth earns a score of 39/100.
Cytek Biosciences, Inc. carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.04, Cytek Biosciences, Inc. holds $5.04 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 90/100.
While Cytek Biosciences, Inc. generated -$4.7M in operating cash flow, capex of $4.1M consumed most of it, leaving -$8.8M in free cash flow. This results in a low score of 32/100, reflecting heavy capital investment rather than weak cash generation.
Cytek Biosciences, Inc. generates a -19.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 25/100. This is down from -1.5% the prior year.
Cytek Biosciences, Inc. scores 3.51, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($569.5M) relative to total liabilities ($119.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cytek Biosciences, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Cytek Biosciences, Inc. generates $0.07 in operating cash flow (-$4.7M OCF vs -$66.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cytek Biosciences, Inc. earns $-85.2 in operating income for every $1 of interest expense (-$40.4M vs $474K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Cytek Biosciences, Inc. generated $201.5M in revenue in fiscal year 2025. This represents an increase of 0.5% from the prior year.
Cytek Biosciences, Inc.'s EBITDA was -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 146.5% from the prior year.
Cytek Biosciences, Inc. reported -$66.5M in net income in fiscal year 2025. This represents a decrease of 1005.3% from the prior year.
Cytek Biosciences, Inc. earned $-0.52 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 940.0% from the prior year.
Cash & Balance Sheet
Cytek Biosciences, Inc. generated -$8.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 140.1% from the prior year.
Cytek Biosciences, Inc. held $90.9M in cash against $0 in long-term debt as of fiscal year 2025.
Cytek Biosciences, Inc. had 129M shares outstanding in fiscal year 2025. This represents a decrease of 0.5% from the prior year.
Margins & Returns
Cytek Biosciences, Inc.'s gross margin was 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.6 percentage points from the prior year.
Cytek Biosciences, Inc.'s operating margin was -20.0% in fiscal year 2025, reflecting core business profitability. This is down 9.8 percentage points from the prior year.
Cytek Biosciences, Inc.'s net profit margin was -33.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 30.0 percentage points from the prior year.
Cytek Biosciences, Inc.'s ROE was -19.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.0 percentage points from the prior year.
Capital Allocation
Cytek Biosciences, Inc. invested $36.5M in research and development in fiscal year 2025. This represents a decrease of 7.4% from the prior year.
Cytek Biosciences, Inc. spent $15.1M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 30.2% from the prior year.
Cytek Biosciences, Inc. invested $4.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 15.9% from the prior year.
CTKB Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.1M-29.0% | $62.1M+18.8% | $52.3M+14.7% | $45.6M+10.0% | $41.5M-27.9% | $57.5M+11.6% | $51.5M+10.5% | $46.6M |
| Cost of Revenue | $22.9M-21.8% | $29.3M+18.2% | $24.7M+13.8% | $21.7M+2.0% | $21.3M-10.6% | $23.8M+5.9% | $22.5M+6.2% | $21.2M |
| Gross Profit | $21.3M-35.4% | $32.9M+19.4% | $27.6M+15.4% | $23.9M+18.4% | $20.2M-40.1% | $33.7M+16.0% | $29.0M+14.0% | $25.4M |
| R&D Expenses | $9.6M+7.2% | $9.0M+0.1% | $9.0M+1.5% | $8.8M-9.2% | $9.7M0.0% | $9.7M-1.6% | $9.9M-1.2% | $10.0M |
| SG&A Expenses | $18.5M+12.7% | $16.4M+1.6% | $16.1M+19.1% | $13.5M+4.9% | $12.9M+42.2% | $9.1M-17.1% | $10.9M-6.4% | $11.7M |
| Operating Income | -$18.5M-230.1% | -$5.6M+39.2% | -$9.2M+13.5% | -$10.6M+29.1% | -$15.0M-601.5% | $3.0M+170.3% | -$4.2M+50.2% | -$8.5M |
| Interest Expense | $262K+136.1% | -$725K-246.8% | $494K+19.3% | $414K+42.3% | $291K+104.9% | -$5.9M-5085.7% | $119K-11.2% | $134K |
| Income Tax | $1.5M-96.3% | $40.0M+1847.9% | -$2.3M-92.2% | -$1.2M-976.5% | $136K-80.0% | $680K+186.7% | -$784K-124.1% | $3.2M |
| Net Income | -$18.9M+57.2% | -$44.1M-704.6% | -$5.5M+1.9% | -$5.6M+51.0% | -$11.4M-218.3% | $9.6M+924.7% | $941K+109.0% | -$10.4M |
| EPS (Diluted) | $-0.15 | N/A | $-0.040.0% | $-0.04+55.6% | $-0.09 | N/A | $0.01+112.5% | $-0.08 |
CTKB Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $449.1M-2.7% | $461.5M-6.7% | $494.9M+0.3% | $493.3M+2.2% | $482.6M-3.4% | $499.5M+1.7% | $491.2M+1.6% | $483.7M |
| Current Assets | $379.3M-3.2% | $392.0M+0.9% | $388.5M+1.5% | $382.8M+0.6% | $380.5M-4.0% | $396.4M+1.6% | $390.2M+1.6% | $384.1M |
| Cash & Equivalents | $65.7M-27.7% | $90.9M-2.6% | $93.3M+23.6% | $75.5M-20.8% | $95.3M-3.5% | $98.7M-39.2% | $162.3M-8.8% | $177.9M |
| Inventory | $49.8M+2.8% | $48.4M-6.2% | $51.6M+4.4% | $49.5M+9.1% | $45.3M+3.3% | $43.9M-6.2% | $46.8M-6.5% | $50.1M |
| Accounts Receivable | $51.9M-17.0% | $62.5M+10.4% | $56.6M+0.7% | $56.2M+2.2% | $55.0M-9.2% | $60.6M+15.1% | $52.6M+17.9% | $44.6M |
| Goodwill | $16.7M0.0% | $16.7M0.0% | $16.7M-0.1% | $16.7M+0.2% | $16.7M+0.1% | $16.7M+3.0% | $16.2M0.0% | $16.2M |
| Total Liabilities | $121.5M+1.4% | $119.8M+3.0% | $116.3M+0.5% | $115.8M+12.4% | $103.0M-0.8% | $103.8M-1.9% | $105.8M+11.8% | $94.6M |
| Current Liabilities | $80.9M+4.0% | $77.8M+3.5% | $75.2M+2.6% | $73.3M+8.2% | $67.7M0.0% | $67.7M+7.7% | $62.8M+19.9% | $52.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $327.6M-4.1% | $341.7M-9.7% | $378.6M+0.3% | $377.6M-0.5% | $379.6M-4.1% | $395.7M+2.7% | $385.5M-0.9% | $389.1M |
| Retained Earnings | -$120.6M-18.5% | -$101.7M-76.4% | -$57.7M-10.5% | -$52.2M-12.0% | -$46.6M-32.4% | -$35.2M+21.5% | -$44.8M+2.1% | -$45.8M |
CTKB Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M-254.9% | -$771K+80.2% | -$3.9M-3709.3% | $108K+186.4% | -$125K-106.3% | $2.0M-84.9% | $13.2M+113.1% | $6.2M |
| Capital Expenditures | $2.2M+116.6% | $1.0M+52.4% | $657K-58.3% | $1.6M+85.7% | $849K-5.0% | $894K-11.6% | $1.0M-4.0% | $1.1M |
| Free Cash Flow | -$4.9M-176.7% | -$1.8M+61.1% | -$4.6M-210.1% | -$1.5M-50.8% | -$974K-188.3% | $1.1M-91.0% | $12.2M+137.0% | $5.2M |
| Investing Cash Flow | -$27.1M-1370.1% | -$1.8M-109.7% | $18.9M+215.3% | -$16.4M-273.6% | $9.5M+114.9% | -$63.4M-301.2% | -$15.8M-881.8% | $2.0M |
| Financing Cash Flow | $4.0M+424.7% | -$1.2M-163.2% | $1.9M+174.6% | -$2.6M+77.5% | -$11.5M-217.2% | -$3.6M+69.9% | -$12.1M-606.3% | -$1.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0+100.0% | -$34K-17.2% | -$29K-100.6% | $4.5M-57.6% | $10.6M+51.8% | $7.0M-41.2% | $11.9M+340.7% | $2.7M |
CTKB Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.2%-4.8pp | 52.9%+0.2pp | 52.7%+0.4pp | 52.3%+3.7pp | 48.6%-9.9pp | 58.6%+2.2pp | 56.3%+1.8pp | 54.6% |
| Operating Margin | -41.8%-32.8pp | -9.0%+8.6pp | -17.6%+5.7pp | -23.3%+12.8pp | -36.1%-41.3pp | 5.2%+13.5pp | -8.3%+10.0pp | -18.3% |
| Net Margin | -42.8%+28.2pp | -70.9%-60.5pp | -10.5%+1.8pp | -12.2%+15.3pp | -27.5%-44.3pp | 16.8%+14.9pp | 1.8%+24.2pp | -22.4% |
| Return on Equity | -5.8%+7.1pp | -12.9%-11.4pp | -1.5%+0.0pp | -1.5%+1.5pp | -3.0%-5.4pp | 2.4%+2.2pp | 0.2%+2.9pp | -2.7% |
| Return on Assets | -4.2%+5.3pp | -9.6%-8.4pp | -1.1%+0.0pp | -1.1%+1.2pp | -2.4%-4.3pp | 1.9%+1.7pp | 0.2%+2.4pp | -2.2% |
| Current Ratio | 4.69-0.4 | 5.04-0.1 | 5.17-0.1 | 5.22-0.4 | 5.62-0.2 | 5.86-0.4 | 6.21-1.1 | 7.33 |
| Debt-to-Equity | 0.37+0.0 | 0.35+0.0 | 0.310.0 | 0.31+0.0 | 0.270.0 | 0.26-0.0 | 0.27+0.0 | 0.24 |
| FCF Margin | -11.1%-8.3pp | -2.9%+5.9pp | -8.7%-5.5pp | -3.2%-0.9pp | -2.4%-4.3pp | 1.9%-21.8pp | 23.7%+12.7pp | 11.1% |
Similar Companies
Frequently Asked Questions
What is Cytek Biosciences, Inc.'s annual revenue?
Cytek Biosciences, Inc. (CTKB) reported $201.5M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cytek Biosciences, Inc.'s revenue growing?
Cytek Biosciences, Inc. (CTKB) revenue grew by 0.5% year-over-year, from $200.5M to $201.5M in fiscal year 2025.
Is Cytek Biosciences, Inc. profitable?
No, Cytek Biosciences, Inc. (CTKB) reported a net income of -$66.5M in fiscal year 2025, with a net profit margin of -33.0%.
What is Cytek Biosciences, Inc.'s EBITDA?
Cytek Biosciences, Inc. (CTKB) had EBITDA of -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cytek Biosciences, Inc.'s gross margin?
Cytek Biosciences, Inc. (CTKB) had a gross margin of 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cytek Biosciences, Inc.'s operating margin?
Cytek Biosciences, Inc. (CTKB) had an operating margin of -20.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cytek Biosciences, Inc.'s net profit margin?
Cytek Biosciences, Inc. (CTKB) had a net profit margin of -33.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cytek Biosciences, Inc.'s return on equity (ROE)?
Cytek Biosciences, Inc. (CTKB) has a return on equity of -19.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cytek Biosciences, Inc.'s free cash flow?
Cytek Biosciences, Inc. (CTKB) generated -$8.8M in free cash flow during fiscal year 2025. This represents a -140.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cytek Biosciences, Inc.'s operating cash flow?
Cytek Biosciences, Inc. (CTKB) generated -$4.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cytek Biosciences, Inc.'s total assets?
Cytek Biosciences, Inc. (CTKB) had $461.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cytek Biosciences, Inc.'s capital expenditures?
Cytek Biosciences, Inc. (CTKB) invested $4.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cytek Biosciences, Inc. spend on research and development?
Cytek Biosciences, Inc. (CTKB) invested $36.5M in research and development during fiscal year 2025.
What is Cytek Biosciences, Inc.'s current ratio?
Cytek Biosciences, Inc. (CTKB) had a current ratio of 5.04 as of fiscal year 2025, which is generally considered healthy.
What is Cytek Biosciences, Inc.'s debt-to-equity ratio?
Cytek Biosciences, Inc. (CTKB) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cytek Biosciences, Inc.'s return on assets (ROA)?
Cytek Biosciences, Inc. (CTKB) had a return on assets of -14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cytek Biosciences, Inc.'s cash runway?
Based on fiscal year 2025 data, Cytek Biosciences, Inc. (CTKB) had $90.9M in cash against an annual operating cash burn of $4.7M. This gives an estimated cash runway of approximately 233 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cytek Biosciences, Inc.'s Altman Z-Score?
Cytek Biosciences, Inc. (CTKB) has an Altman Z-Score of 3.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cytek Biosciences, Inc.'s Piotroski F-Score?
Cytek Biosciences, Inc. (CTKB) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cytek Biosciences, Inc.'s earnings high quality?
Cytek Biosciences, Inc. (CTKB) has an earnings quality ratio of 0.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cytek Biosciences, Inc. cover its interest payments?
Cytek Biosciences, Inc. (CTKB) has an interest coverage ratio of -85.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cytek Biosciences, Inc.?
Cytek Biosciences, Inc. (CTKB) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.